The Benevolent TEAM
Chairman and Founder
Ken is a serial entrepreneur, investor and healthcare and technology veteran with more than 20 years of business leadership experience. He was previously CEO of Proximagen, a UK-based biotech company committed to delivering novel drugs and innovative new treatments for central nervous system (CNS) disorders. Following the acquisition of this business, Ken began to think deeply about the drug discovery landscape. He founded BenevolentAI with two very specific ambitions: firstly, to build a technology that could ingest all of the world's available bioscience information, and secondly, to create a “thinking” technology to reason on all of that data, making new knowledge available to scientists and their research.
His vision was to reinvent the entire end-to-end drug development process, and disrupt the pharmaceutical industry’s fragmented and inefficient knowledge ecosystem. Only a revolutionary change would be able to harness artificial intelligence, creating a fundamental shift in the way we understand disease and a pathway to developing better medicines for patients, faster. Ken has grown BenevolentAI into the pre-eminent AI-enabled, fully integrated pharmaceutical discovery and clinical development company, with the world’s largest, most sophisticated bioscience knowledge base. His team stay true to his founding vision, maximising the value that AI can deliver to patients and their families.
Board of Directors
Our board bring deep experience and expertise from the worlds of technology, life sciences and biotech, as well as government and business development.
Joanna is a tech industry veteran with over 25 years' experience building and scaling global companies including Facebook, Bebo, Aol, Google, Real Networks and Efi. Prior to joining Benevolent AI, she served in UK Government as Under Secretary of State and Minister for Internet Safety & Security, Digital Economy Adviser and Chair and CEO of TechCityUK. Joanna is passionate about creating responsible technology that benefits humanity. She is a leading advocate for children's rights and safety online and founder of the WeProtect Global Alliance.
Chief Executive, Clinical Programmes & Strategic Relationships
Professor Jackie Hunter held senior positions at global pharmaceutical organisations including GSK, Proximagen and OI Pharma Partners before joining BenevolentAI as a Director in 2016. She brings vast academic and business experience in the biomedical and pharmaceutical sectors. She directs the application of BenevolentAI’s technology for clinical development and gives the company the insight it needs to operate its unique business model – one which sees it not only researching, but also developing the blueprint for new drugs.
Co-Founder & Head of Corporate Development
A senior corporate finance executive with over 15 years' experience in capital markets, Michael left the City in 2009 to join Ken Mulvany at Proximagen. He undertook the role of Head of Corporate Development, focusing on fundraising, corporate transactions, and business development. Following the successful acquisition of Proximagen, Mike joined the founding team at BenevolentAI, leading corporate development and the continued growth of the business.
Non Executive Director
Bart is a disruptive technology industry leader, having held senior positions at some of the world’s most respected technology companies. Bart previously served on the boards of DeepMind, Summly and Onavo, acquired by Google, Yahoo and Facebook respectively. Bart is currently an Advisor to Horizons Ventures and holds Directorships with Viv Labs, Sentient Technologies, Cortica Ltd, Shine Security, Zoom.us, Hola, Modern Meadow and Impossible Foods Inc. among others.
Non Executive Director
Jerome is an expert in the commercialisation of AI. He co-founded Vivisimo, a tech firm specialising in text mining and enterprise search engines, which was acquired by IBM. At IBM he became chief scientist of big data, and created and led the development of the Watson platform - the first comprehensive cloud platform for artificial intelligence. He served as CEO of BenevolentTech between 2016 and 2018 before joining Facebook to lead AI research as VP of AI.
Our passionate leadership team brings experience from businesses in technology, science and consulting, and guides cross-functional practice at BenevolentAI.
SVP AI Research
SVP Strategy and Operations
VP Product management
SVP Drug Discovery
Co-founder and SVP Partnerships
VP Corporate Affairs
SVP Data Science & GM USA
VP Translational Medicine
VP Biomedical Informatics
SVP Business Development
SVP Design & Operations
SVP Group Finance